Honorary Professorship

Published: 12 June 2020

Dr Richard Goodwin, an Imaging Scientist with long-standing links to the Institute and Glasgow Polyomics, has been recognised for his outstanding achievements in the fields of imaging, omics and data integration and a commitment to fostering excellence in research.

A cropped head and shoulders shot of Dr Richard Goodwin beside UofG logo

An Imaging Scientist with long-standing links to the Institute of Infection, Immunity & Inflammation and Glasgow Polyomics has received an Honorary Professorship from the University of Glasgow.

Dr Richard Goodwin, Head of Imaging & AI for AstraZeneca, was recently recognised for his outstanding achievements in the fields of imaging, omics and data integration and a commitment to fostering excellence in research.

Dr Goodwin developed mass spectrometry imaging for proteomics in Glasgow, working as a postdoctoral fellow in the Sir Henry Wellcome Functional Genomics Facility - now Glasgow Polyomics - before moving to AstraZeneca, first in Sweden and then back in the UK.

He has made a substantial contribution to the development of mass spectrometry imaging to study drug metabolism and disposition and, through his academic collaborations, to the application of MSI to understand health and disease.

Richard also continued to collaborate with colleagues in iii, including supervising a number of joint PhD students between the Institute and AstraZeneca in Cambridge.

These have covered topics around infection/immunology, the effects of the intestinal microbiome on host health, and more recently the relevance of microbial metabolites in driving systemic inflammation associated with Crohn’s disease.  

This included extended periods of training for these PhD students at the AstraZeneca campus in Cambridge, where they have been taught advance mass spectrometry and imaging techniques.

Dr Richard Burchmore, Head of Mass Spectrometry at Glasgow Polyomics, said: “Richard Goodwin plays a prominent role in the development of molecular imaging approaches that are transforming pharmaceutical research.

"Through his academic collaborations, he is supporting wider applications of these new technologies across biology.

"His new appointment as Honorary Professor in our Institute will formalise and support these collaborations and, in particular, will provide a mechanism to develop our teaching in this dynamic, technology-driven research area. Congratulations, Richard!"


First published: 12 June 2020